NYSE - Delayed Quote • USD
AbbVie Inc. (ABBV)
At close: April 23 at 4:00 PM EDT
After hours: April 23 at 7:36 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 13 | 14 | 17 | 23 |
| Avg. Estimate | 2.23 | 2.81 | 11.1 | 12.15 |
| Low Estimate | 2.18 | 2.62 | 10.86 | 11.42 |
| High Estimate | 2.3 | 2.92 | 11.37 | 13.22 |
| Year Ago EPS | 2.46 | 2.91 | 11.11 | 11.1 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 15 | 14 | 25 | 24 |
| Avg. Estimate | 11.92B | 13.57B | 54.6B | 57.9B |
| Low Estimate | 11.86B | 12.99B | 53.86B | 55.72B |
| High Estimate | 11.98B | 13.82B | 55.76B | 60.8B |
| Year Ago Sales | 12.22B | 13.87B | 54.32B | 54.6B |
| Sales Growth (year/est) | -2.50% | -2.20% | 0.50% | 6.00% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | 2.46 | 2.81 | 2.86 | 2.77 |
| EPS Actual | 2.46 | 2.91 | 2.95 | 2.79 |
| Difference | 0 | 0.1 | 0.09 | 0.02 |
| Surprise % | 0.00% | 3.60% | 3.10% | 0.70% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 2.23 | 2.81 | 11.1 | 12.15 |
| 7 Days Ago | 2.21 | 2.8 | 11.11 | 12.19 |
| 30 Days Ago | 2.34 | 2.81 | 11.19 | 12.2 |
| 60 Days Ago | 2.35 | 2.8 | 11.19 | 12.23 |
| 90 Days Ago | 2.48 | 2.84 | 11.23 | 12.25 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | 1 |
| Up Last 30 Days | 1 | 5 | 3 | 2 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 3 | -- | 3 | 1 |
Growth Estimates
| CURRENCY IN USD | ABBV | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -9.30% | -- | -- | 0.40% |
| Next Qtr. | -3.40% | -- | -- | 9.90% |
| Current Year | -0.10% | -- | -- | 4.30% |
| Next Year | 9.50% | -- | -- | 13.40% |
| Next 5 Years (per annum) | 6.34% | -- | -- | 11.09% |
| Past 5 Years (per annum) | 8.87% | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | Barclays: Overweight to Overweight | 3/27/2024 |
| Maintains | Guggenheim: Buy to Buy | 3/22/2024 |
| Maintains | Truist Securities: Buy to Buy | 2/6/2024 |
| Maintains | Raymond James: Outperform | 2/6/2024 |
| Maintains | BMO Capital: Outperform to Outperform | 2/5/2024 |
| Maintains | Raymond James: Outperform to Outperform | 2/5/2024 |
Related Tickers
MRK Merck & Co., Inc.
126.88
-0.05%
BMY Bristol-Myers Squibb Company
48.99
-0.31%
JNJ Johnson & Johnson
149.56
+0.30%
AMGN Amgen Inc.
273.54
+0.60%
LLY Eli Lilly and Company
745.69
+1.96%
PFE Pfizer Inc.
26.32
+0.23%
GILD Gilead Sciences, Inc.
67.03
+0.12%
AZN AstraZeneca PLC
70.85
+1.03%
GSK GSK plc
41.24
+1.60%
NVS Novartis AG
97.28
+2.27%